http://www.istarmed.com/wp-content/uploads/2020/10/Logo-iSTAR-Med-web-300x138.png00Katherin Awadhttp://www.istarmed.com/wp-content/uploads/2020/10/Logo-iSTAR-Med-web-300x138.pngKatherin Awad2021-03-23 08:00:422021-03-19 03:53:19STAR-II promising results in Ophthalmology Times
CEO Michel Vanbrabant will present the company’s latest positive developments and an ambitious 2021 roadmap for iSTAR Medical at the Biocapital Europe meeting on 11 March.
http://www.istarmed.com/wp-content/uploads/2020/10/Logo-iSTAR-Med-web-300x138.png00Katherin Awadhttp://www.istarmed.com/wp-content/uploads/2020/10/Logo-iSTAR-Med-web-300x138.pngKatherin Awad2021-03-09 09:00:362021-03-05 01:24:11iSTAR Medical 2021 roadmap at BioCapital Europe
The 12-month results from the European STAR-II trial of iSTAR Medical’s minimally-invasive glaucoma surgery (MIGS) device MINIjectTM will be presented at the American Glaucoma Society (AGS) meeting.
An article in Ophthalmology Times Europe outlines how the suprachoroidal space promises to become a feasible route to effectively reduce intraocular pressure (IOP) in patients with glaucoma, thanks to iSTAR Medical’s minimally-invasive glaucoma surgery (MIGS) device MINIjectTM.
http://www.istarmed.com/wp-content/uploads/2020/10/Logo-iSTAR-Med-web-300x138.png00Katherin Awadhttp://www.istarmed.com/wp-content/uploads/2020/10/Logo-iSTAR-Med-web-300x138.pngKatherin Awad2021-02-04 12:21:032021-02-04 12:30:14MINIject in Ophthalmology Times Europe
In the latest issue of Glaucoma Physician, iSTAR Medical’s minimally-invasive glaucoma surgery (MIGS) device MINIjectTM features as a prominent solution to unlock the potential of the suprachoroidal space in glaucoma treatment.
STAR-II promising results in Ophthalmology Times
/in News /by Katherin AwadThe six and 12-month results from the STAR-II trial on MINIjectTM have been reported in the latest issue of Ophthalmology Times.
iSTAR Medical 2021 roadmap at BioCapital Europe
/in News /by Katherin AwadCEO Michel Vanbrabant will present the company’s latest positive developments and an ambitious 2021 roadmap for iSTAR Medical at the Biocapital Europe meeting on 11 March.
MINIject STAR-II 12-month trial results at AGS
/in News /by Katherin AwadThe 12-month results from the European STAR-II trial of iSTAR Medical’s minimally-invasive glaucoma surgery (MIGS) device MINIjectTM will be presented at the American Glaucoma Society (AGS) meeting.
MINIject in Ophthalmology Times Europe
/in News /by Katherin AwadAn article in Ophthalmology Times Europe outlines how the suprachoroidal space promises to become a feasible route to effectively reduce intraocular pressure (IOP) in patients with glaucoma, thanks to iSTAR Medical’s minimally-invasive glaucoma surgery (MIGS) device MINIjectTM.
MINIject in Glaucoma Physician journal
/in News /by Katherin AwadIn the latest issue of Glaucoma Physician, iSTAR Medical’s minimally-invasive glaucoma surgery (MIGS) device MINIjectTM features as a prominent solution to unlock the potential of the suprachoroidal space in glaucoma treatment.